BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 10348267)

  • 1. Amifostine and combined-modality therapeutic approaches.
    Mehta MP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in non-small cell lung cancer.
    Schiller JH
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioprotective effects of amifostine.
    Wasserman T
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
    Mehta MP
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing considerations with amifostine: a review of the literature and clinical experience.
    Dorr RT; Holmes BC
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):108-19. PubMed ID: 10348269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
    Grdina DJ; Hunter N; Kataoka Y; Murley JS; Milas L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):22-7. PubMed ID: 10348256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics of amifostine in ovarian cancer.
    Calhoun EA; Bennett CL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection by amifostine of cyclophosphamide-induced myelosuppression.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in gynecologic cancer.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.